Hassan Hashmi, General and Colorectal Surgeon at Las Vegas Surgical Associates, shared a post on LinkedIn:
“Important RCT data from the ORCHESTRA trial published in JAMA highlights a critical point in metastatic colorectal cancer care.
Even when >80% tumor debulking is feasible in multiorgan metastatic colorectal cancer, adding local debulking to chemotherapy does not translate into a survival benefit and is associated with higher serious adverse events.
It highlights that biology often outweighs technical feasibility.
Thought-provoking implications for how we approach cytoreduction in advanced disease.”
Title: Tumor Debulking in Combination With Chemotherapy in Multiorgan Metastatic Colorectal Cancer
Authors: Elske C. Gootjes, Lotte Bakkerus, Anviti A. Adhin, Barbara M. Zonderhuis, Kathelijn S. Versteeg, Jurriaan B. Tuynman, Martijn R. Meijerink, Cornelis J. A. Haasbeek, Johannes H. W. de Wilt, Dirk J. Grunhagen, Ewoud J. Smit, John M. Primrose, John Bridgewater, Esther van Meerten, Jan-Willem B. de Groot, Mathijs P. Hendriks, Esther Oomen-de Hoop, Tineke E. Buffart, Cornelis Verhoef, Henk M. W. Verheul
Read the full article on JAMA.
Other articles featuring Hassan Hashmi on OncoDaily.
